Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20; 368(25):2385-94.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.